UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
The National Health Service (NHS) has prescribed Novo Nordisk A/S's (NYSE:NVO) weight-loss drug Wegovy far less often than anticipated, struggling with a shortage of weight management clinics required to distribute the popular treatment.
國家醫療服務系統(NHS)開具Novo Nordisk A/S (NYSE: 紐交所 NVO)的減肥藥物Wegovy的次數遠低於預期,因爲缺乏分發這種熱門治療方法所需的減重診所。
Since its launch, the drug has been prescribed just 3,300 times, significantly below the 13,500 patients expected to receive it in its first year, according to a Financial Times analysis of NHS England data.
自推出以來,根據英國國家醫療保健服務數據,該藥物已經開出的處方僅有3,300次,顯著低於預計會在第一年得到它的13,500名病人。
Demand for Wegovy is set to increase following the Medicines and Healthcare Products Regulatory Agency's (MHRA) approval for its use in reducing the risk of serious heart problems or strokes in overweight and obese adults.
由於藥品管理局(MHRA)批准了Wegovy用於減輕超重和肥胖成年人患嚴重心血管問題或中風的風險,對Wegovy的需求有望增加。
Despite this, the drug is in short supply internationally. The NHS has prioritized supplies of Ozempic, another drug by Novo Nordisk that uses the same active ingredient but is designated for type-2 diabetes, over Wegovy.
儘管如此,該藥物在國際上供應短缺。英國國家醫療服務系統已優先供應了另一種使用相同活性成分但被指定用於2型糖尿病的諾和諾德公司藥品Ozempic而不是Wegovy。
Also Read: Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications.
此外,狂熱地追求使用Ozempic和Zepbound減肥的病人讓糖尿病患者失去了重要的GLP-1類藥物。
The shortfall in Wegovy prescriptions is also attributed to the lack of specialist NHS weight-loss services.
Wegovy處方不足也歸咎於NHS缺乏專業減重服務。
According to the National Institute of Health and Care Excellence (NICE) guidelines, the NHS can prescribe Wegovy through these services to people with a BMI over 35 or over 30 with another weight-related condition for up to two years.
根據國家衛生和護理卓越研究所(NICE)的指南,NHS可以通過這些服務向BMI超過35或BMI超過30,且有其他與體重相關的疾病的人開具Wegovy處方,最長達兩年。
However, there are only around 20 of these "tier 3" services across the U.K., with some NHS trusts reporting long waiting lists.
然而,英國僅有大約20個這些“三級”服務,一些NHS信託機構報告長時間等待名單。
NHS prescriptions of Wegovy have increased each month since its approval in the U.K. last year, reaching approximately 770 in April.
自去年在英國獲批以來, Wegovy的英國國家醫療服務系統處方每個月都在增加,到4月約爲770個。
This number is likely to rise further, with an estimated 4 million Britons expected to meet the drug guidelines by 2027.
隨着預計將有400萬英國人符合藥品指南,這個數字很可能會進一步上升。
NICE anticipates nearly 50,000 patients annually will receive semaglutide, the active ingredient in Wegovy, via the NHS.
英國國家衛生保健研究所預計每年將有近50,000名患者通過英國國家醫療服務系統獲得Wegovy所含活性成分semaglutide的治療。
Despite prioritizing Ozempic supply to ensure type-2 diabetes patients receive necessary treatment, citing Novo Nordisk, the FT report stated it has "made it a priority to provide a protected supply of Wegovy to the NHS."
儘管優先供應Ozempic以確保2型糖尿病患者接受必要治療,但據FT報道,英國國家醫療保健服務系統已“將向英國國家醫療保健服務系統提供一種受保護的Wegovy供應”成爲其優先任務,同時也引用了諾和諾德公司。
However, the company did not disclose the number of drugs available through the health service.
然而,該公司並未披露通過該醫療服務所提供的藥物數量。
In the U.K., GLP-1 drugs, including Wegovy, are expected to be in short supply until at least the end of 2024.
在英國,包括Wegovy在內的GLP-1類藥物預計至少到2024年供應短缺。
Price Action: NVO shares are trading lower by 1.46% to $131.34 at the last check on Wednesday.
價格走勢:NVO的股價在週三最後一次檢查時下跌1.46%,爲131.34美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明:本內容部分使用人工智能工具生成,並經Benzinga編輯審核發佈。
- Oral Weight Loss Drugs Vs. Injections – Pills Are Promising Yet Challenging Frontier.
- 口服減肥藥與注射減肥藥—藥片是一片充滿希望但具有挑戰性的前沿。
Photo by Tobias Arhelger via Shutterstock
圖片由shutterstock提供